Clinical trial

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults…

NCT00391729 · Abbott, Industry · Completed

Key facts

NCT number NCT00391729
Title A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Official title A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor Abbott, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Attention-Deficit/Hyperactivity Disorder
Intervention type Drug
Interventions ABT-089, Placebo
Enrollment 221
Start date Oct 1, 2006
Primary completion Jun 1, 2007
Completion Jun 1, 2007
First posted Oct 24, 2006
Last update posted Oct 18, 2011
Countries United States

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies